All News

Article

IV Secukinumab for AxSpa

Eric Dein, MD

The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. Data for this new approval will be presented at ACR Convergence on November 14th by Dr. Atul Deodhar.

Janet Pope Tweet
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Aurelie Najm Tweet
HCQ and risk of retinopathy 👁️ DoD database HCQ 44000+ females & 10000+ males Risk retinopathy HR 1.5 Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7 No adjustment on HCQ dose @RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45
Aurelie Najm Tweet
And to continue B-SAFE Clinical risk score for HCQ retinopathy 👁️ 10 years 4000+ pts, 3% retinopathy over 5yrs Predictors of HCQ retinopathy -body weight -sex -age -eGFR -weight based dose mg/kg -higher cumulative dose Risk ranges 1% to >20% @RheumNow #ACR23 ABST2453 https://t.co/h2tl6vH9M3 https://t.co/8iuRxoVaJ0
Richard Conway Tweet
Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o
Eric Dein Tweet
A#2429 #ACR23 @RheumNow ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk Mean prednisolone dose 6.6 mg H/o fragility fx in 1/2 pts 12 mo: Increase in spine BMD- ROMO (+7) and DEN (+2) Hip and Femoral neck improved both (1.6% both), not signif diff bw grps AEs: incr injxn site rxn https://t.co/VueuZIjFfM
TheDaoIndex Tweet
KDAO2011
Who knew @FDA_Drug_Info presented #ACR23 posters?! I thought they just issue statements if there was information to be shared! Abst#1822 Bari and Toci use during the pandemic for #COVID19 did not show new safety signals. 1 case HBV reactivation with bari @RheumNow https://t.co/zd7TELsV2j
Mike Putman Tweet
EBRheum
Interesting counterpoint to a tweet from a few days ago re:black box warning for JAKs No change in utilization rates post black box... maybe people had already baked this into the cake by then? @RheumNow #ACR23 Abstr 2142 https://t.co/K9cWbRSWV6
Md Yuzaiful Md Yusof Tweet
#ACR23 Late-Breaking Abstr#L09 In a crowded market, you’ve got to stand out. Phase 2 RCT of LNK01001, a highly selective JAK1-i in China: improvement in ACR 20,50,70 vs PBO at WK12. Those in PBO who didn’t meet ACR20 improved after receiving Tx. Very low infections @RheumNow https://t.co/ZbJFNHOtFT
Eric Dein Tweet
Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi
Mike Putman Tweet
EBRheum
Excellent pragmatic RCT, TNF withdrawal in RA Almost 2/3 flared by 1 yr; at 3 years up to 3 in 4 Supports my practice of generally continuing TNFs long term Also highlights importance of pt preferences; 1 in 4 may do well if they wish to discontinue @RheumNow #ACR23 #ACRBest https://t.co/G4l0DgBP2Z
Janet Pope Tweet
Age does NOT affect the chance of getting irAE or the severity when using check point inhibitors to treat cancer. Data from #CANRIO database in #Canada #ACR 23 @ACRheum @RheumNow #1063 https://t.co/bqbiXzdAqr
Mike Putman Tweet
EBRheum
Obs study, bDMARDs & malignancy TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs I'm a little skeptical... KM curves diverged w/~45 days, seems implausible? Agree w/first author, possible channeling bias @RheumNow #ACR23 Abstr 1678 https://t.co/1uL3j6kTSj
Richard Conway Tweet
Sendaydiego et al. Comparative cancer safety b/tsDMARDs. 37,026 patient database cohort study. Compared to TNFi, RTX HR 2.2 (1.5, 3.3) ABA HR 1.7 (1.3-2.4), JAKi HR 1.3 (0.9-1.9). Abstr#1678 #ACR23 @RheumNow https://t.co/bTNtaNJrln https://t.co/qQBM2F2q8N
Aurelie Najm Tweet
Ritux (OR 2.2), ABA (OR 1.3), JAKi (OR 1.3) significantly increase risk of cancer vs. TNFi Cohort of 37000+ RA pts starting bio/tsDMARDs (379 incident cancers) True biologic effect or confounding by indication in a generally more comorbid population? @RheumNow #ACR23 ABST1678 https://t.co/suj6mVBEC0
Aurelie Najm Tweet
2 RA cohorts w/Breast Cancer 17% TNFi within 1yr after surgery No diff in overall survival at 5 yr w/ TNFi or csDMARD Trend towards better BC specific survival w/ TNFi vs. csDMARD only Worst survival for GC>7.5mg/day Only 2 yrs follow up @RheumNow #ACR23 ABST1675 https://t.co/ekKlJ2dP5i
Robert B Chao, MD Tweet
Does TNFi use in pts with RA and early breast cancer affect survival? TNFi did not affect overall survival or breast cancer specific survival compared to cDMARDs Steroids did increase mortality @RheumNow #ACR23 Abs#1675
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×